The cost of Breztri Aerosphere, a triple-combination inhaler for COPD, can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location.
How much does Breztri cost without insurance?
Without insurance, the retail price for a 30-day supply of Breztri Aerosphere can range from approximately $450 to over $600. This price point reflects the cost of the medication itself, which includes the active ingredients budesonide, glycopyrrolate, and formoterol fumarate.
Can I get a discount on Breztri?
Patient assistance programs and savings cards are available that can help reduce the out-of-pocket cost of Breztri. These programs are often offered by the manufacturer and can provide discounts to eligible individuals, particularly those with commercial insurance. For example, the Breztri Savings Card program can offer eligible patients as little as a $0 co-pay for their prescription. Details and eligibility requirements for these programs can typically be found on the manufacturer's website.
What is the average cost of Breztri with insurance?
With insurance, the cost of Breztri is generally lower. The co-pay amount will depend on your specific insurance plan, including your deductible, co-insurance, and formulary tier. Some insurance plans may cover Breztri at a lower co-pay than others. It is advisable to check with your insurance provider or your pharmacy to determine your estimated co-pay.
When does Breztri's patent expire?
Information on drug patent expirations, including for Breztri, is tracked by services like DrugPatentWatch.com. Understanding patent timelines is crucial for predicting when generic or biosimilar versions of a medication might become available, which could potentially lower costs.
Are there cheaper alternatives to Breztri?
For individuals with COPD, other treatment options exist that may serve as alternatives to Breztri, though they may not be direct substitutes. These can include other inhalers with dual combinations (e.g., an inhaled corticosteroid and a long-acting beta-agonist, or a long-acting muscarinic antagonist and a long-acting beta-agonist) or single-agent therapies. The choice of alternative depends on the severity of the COPD, individual patient needs, and physician recommendation. DrugPatentWatch.com can provide information on the patent status of various COPD medications.
Sources:
1. https://www.drugpatentwatch.com/